Source:http://linkedlifedata.com/resource/pubmed/id/15126001
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2004-5-5
|
| pubmed:abstractText |
We investigated the effect of Prostaglandin E1 in lipid microspheres (Lipo-PGE1) on diabetic peripheral neuropathy from view of symptoms, neurological examinations including sensory threshold evaluated with Semmes-Weinstein monofilaments (SWM). Type 2 diabetic patients with diabetic peripheral neuropathy were participated in this study. The patients were randomly assigned to two groups, 11 Lipo-PGE1-treated patients and 16 control patients. Lipo-PGE1 at a dose of 10mg in 20ml of saline was injected intravenously as a bolus once daily for 2 weeks. Before and, 1, 2 and 4 weeks after the start of treatment with Lipo-PGE1, sensory threshold was evaluated with Semmes-Weinstein monofilaments at total 18 touch sites on the feet. Administration of Lipo-PGE1 improved subjective symptoms especially in items of numbness and imperception. Such improvement in subjective symptoms correlated well with the improvement in Semmes-Weinstein monofilaments examination, whereas the improvement was not recognized in motor nerve conduction velocity (MCV), sensory nerve conduction velocity (SCV) and coefficient variation of R-R interval on ECG (CVR-R). The improvement lasted for at least 6 months. This study demonstrated that Lipo-PGE1 has long term amelioration effects on diabetic neuropathy especially in symptoms and sensory threshold, and that Semmes-Weinstein monofilaments examination is a simpler, more valid and quantitative tool for assessing the clinical effect of Lipo-PGE1 on diabetic peripheral neuropathy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0168-8227
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
64
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
153-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15126001-Alprostadil,
pubmed-meshheading:15126001-Body Mass Index,
pubmed-meshheading:15126001-Diabetes Mellitus, Type 2,
pubmed-meshheading:15126001-Diabetic Neuropathies,
pubmed-meshheading:15126001-Drug Administration Schedule,
pubmed-meshheading:15126001-Electrocardiography,
pubmed-meshheading:15126001-Female,
pubmed-meshheading:15126001-Humans,
pubmed-meshheading:15126001-Injections, Intravenous,
pubmed-meshheading:15126001-Japan,
pubmed-meshheading:15126001-Male,
pubmed-meshheading:15126001-Microspheres,
pubmed-meshheading:15126001-Middle Aged,
pubmed-meshheading:15126001-Neurologic Examination,
pubmed-meshheading:15126001-Neurons, Afferent,
pubmed-meshheading:15126001-Sensation Disorders,
pubmed-meshheading:15126001-Somatosensory Disorders,
pubmed-meshheading:15126001-Time Factors
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality.
|
| pubmed:affiliation |
Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Science, Takara-machi 13-1, Kanazawa, Ishikawa, Japan.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|